Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Grace Therapeutics, Inc GRCE

Healthcare
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel... see more

Recent & Breaking News (NDAQ:GRCE)

Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024

GlobeNewswire 5 days ago

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

GlobeNewswire 10 days ago

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

GlobeNewswire September 25, 2024

Acasti to Present at the Life Sciences Investor Forum

GlobeNewswire September 12, 2024

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 5, 2024

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

GlobeNewswire August 9, 2024

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

GlobeNewswire June 27, 2024

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

GlobeNewswire June 21, 2024

Acasti Pharma to Attend BIO International Convention 2024

GlobeNewswire May 28, 2024

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

GlobeNewswire February 12, 2024

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

GlobeNewswire February 1, 2024

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

GlobeNewswire December 13, 2023

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire November 13, 2023

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

GlobeNewswire October 23, 2023

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

GlobeNewswire October 4, 2023

Acasti Announces $7.5 Million Private Placement Equity Financing

GlobeNewswire September 26, 2023

Acasti to Participate in the H.C. Wainwright Global Investment Conference

GlobeNewswire September 6, 2023

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire August 11, 2023

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

GlobeNewswire August 9, 2023

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

PR Newswire July 10, 2023